Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)

Table 6 Drug-related treatment-emergent adverse events ≥1% in either treatment group (SAF)

TEAEs, n (%)	Placebo (n = 442)	Mirabegron Total (n = 445)
Drug-related TEAEs^a	57 (12.9)	84 (18.9)
Dry mouth	7 (1.6)	6 (1.3)
Nausea	3 (0.7)	6 (1.3)
Constipation	4 (0.9)	3 (0.7)
Diarrhea	1 (0.2)	5 (1.1)
Headache	7 (1.6)	18 (4.0)
Dizziness	6 (1.4)	2 (0.4)
Somnolence	1 (0.2)	2 (0.4)
Escherichia urinary tract infection	7 (1.6)	9 (2.0)
Fatigue	10 (2.3)	7 (1.6)

^aPossible or probable, as assessed by the investigator, or where relationship was missing
SAF safety analysis set, TEAEs treatment-emergent adverse events

ISSN: 1471-2318